Advertisement
Screener

Jade Biosciences, Inc. (JBIO) P/E Ratio

2.8 / 5 stars · 68/120 Roast Me

Jade Biosciences, Inc. PE Ratio

The price-to-earnings (P/E) ratio tells you how many dollars investors pay for each dollar of a company's annual profit. It is market capitalization divided by net income over the trailing four quarters, meaning the four most recent filed quarters added together, and the table shows both amounts. A higher P/E means investors are paying more for each dollar of current earnings, often because they expect profits to grow; a negative P/E means the company lost money over those four quarters. Each point uses the filed share count and the last closing price on or before that quarter-end date, never today's price.

  • Jade Biosciences, Inc. pe ratio for the quarter ending 2026-06-30 was -9.21, a change of -5.7 year-over-year.
  • Jade Biosciences, Inc. pe ratio for the quarter ending 2026-03-31 was -5.34, a change of 24.53 year-over-year.
  • Jade Biosciences, Inc. pe ratio for the quarter ending 2025-12-31 was -5.97, a change of -1.12 year-over-year.
  • Jade Biosciences, Inc. pe ratio for the quarter ending 2025-09-30 was -2.76, a change of 22.01 year-over-year.
  • Jade Biosciences, Inc. pe ratio for fiscal 2026 was -9.21.
  • Jade Biosciences, Inc. pe ratio for fiscal 2025 was -5.97, a change of -1.12 from fiscal 2024.
  • Jade Biosciences, Inc. pe ratio for fiscal 2024 was -4.85, a change of 286.32 from fiscal 2023.
  • Jade Biosciences, Inc. pe ratio for fiscal 2023 was -291.17, a change of 201.02 from fiscal 2022.
Available history
2021-06-30 to 2026-06-30
Data captured

Historical PE Ratio

DatePE RatioMarket capitalizationNet income 12 month
2026-06-30-9.21$1.41B-$153.24M
2026-03-31-5.34$692.08M-$129.61M
2025-12-31-5.97$760.46M-$127.41M
2025-09-30-2.76$278.96M-$100.91M
2025-06-30-3.51$325.13M-$92.6M
2025-03-31-29.87$2.55B-$85.24M
2024-12-31-4.85$340.65M-$70.26M
2024-09-30-24.77$2.11B-$85.24M
2024-06-30-19.06$1.68B-$87.94M
2024-03-31-351.32$28.87B-$82.19M
2023-12-31-291.17$21.99B-$75.52M
2023-09-30-187.28$13.13B-$70.13M
2023-06-30-258.24$16.57B-$64.16M
2023-03-31-306.71$17.52B-$57.12M
2022-12-31-492.19$25.35B-$51.51M
2022-09-30-318.06$14.22B-$44.71M
2022-06-30-358.05$13.36B-$37.31M
2022-03-31-503.68$15.66B-$31.09M
2021-12-31-438.66$10.07B-$22.96M
2021-09-30-973.84$17.92B-$18.41M
2021-06-30-13.37$194.23M-$14.53M

Annual PE Ratio

DatePE RatioMarket capitalizationNet income 12 month
2026-06-30-9.21$1.41B-$153.24M
2025-12-31-5.97$760.46M-$127.41M
2024-12-31-4.85$340.65M-$70.26M
2023-12-31-291.17$21.99B-$75.52M
2022-12-31-492.19$25.35B-$51.51M
2021-12-31-438.66$10.07B-$22.96M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Arbutus Biopharma Corp (ABUS)$0.965B6.19
Kura Oncology, Inc. (KURA)United States$0.967B-3.29
Apnimed, Inc. (APMD)United States$0.899B
RIGEL PHARMACEUTICALS INC (RIGL)United States$0.893B2.25
Theravance Biopharma, Inc. (TBPH)$0.885B16.40
Cryoport, Inc. (CYRX)United States$0.881B-21.29
Corvus Pharmaceuticals, Inc. (CRVS)United States$0.994B-23.25
ARDELYX, INC. (ARDX)United States$0.857B-22.86
Janux Therapeutics, Inc. (JANX)United States$1.019B-9.15
Pacira BioSciences, Inc. (PCRX)United States$1.020B69.03